Massive Bio Completes SOC 2 Type 1 Certification for Its AI Enabled Oncology Technology Platforms Including Patient Centric Clinical Trial Matching and Enrollment Services
NEW YORK–(BUSINESS WIRE)–#ChildhoodCancerAwareness—Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI) enabled…
Pathlock Reinforces Its Leadership in ERP Security and Controls for the AI Era